ZA200103795B - Nitrogen containing heterobicycles as a factor Xa inhibitors. - Google Patents
Nitrogen containing heterobicycles as a factor Xa inhibitors. Download PDFInfo
- Publication number
- ZA200103795B ZA200103795B ZA200103795A ZA200103795A ZA200103795B ZA 200103795 B ZA200103795 B ZA 200103795B ZA 200103795 A ZA200103795 A ZA 200103795A ZA 200103795 A ZA200103795 A ZA 200103795A ZA 200103795 B ZA200103795 B ZA 200103795B
- Authority
- ZA
- South Africa
- Prior art keywords
- biphen
- phenyl
- tetrahydropyrazolo
- trifluoromethyl
- aminobenzisoxazol
- Prior art date
Links
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims description 9
- 229940123583 Factor Xa inhibitor Drugs 0.000 title description 5
- -1 methylenedioxy Chemical group 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 229910052757 nitrogen Inorganic materials 0.000 claims description 64
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 125000005842 heteroatom Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 claims description 19
- 108091008646 testicular receptors Proteins 0.000 claims description 19
- 125000002837 carbocyclic group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 108020002076 NR2 subfamily Proteins 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 8
- 108020000002 NR3 subfamily Proteins 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 108020004021 3-ketosteroid receptors Proteins 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 230000009424 thromboembolic effect Effects 0.000 claims description 5
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 4
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 2
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003971 isoxazolinyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- XZMVYWXGZUMIFK-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one Chemical compound O=C1NCCC2=C1NN=C2 XZMVYWXGZUMIFK-UHFFFAOYSA-N 0.000 claims 3
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- YKPQUSLRUFLVDA-UHFFFAOYSA-N $l^{2}-azanylmethane Chemical compound [NH]C YKPQUSLRUFLVDA-UHFFFAOYSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 101000800807 Homo sapiens Tumor necrosis factor alpha-induced protein 8 Proteins 0.000 claims 1
- 229910014084 Na—B Inorganic materials 0.000 claims 1
- 102100033649 Tumor necrosis factor alpha-induced protein 8 Human genes 0.000 claims 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 125000005438 isoindazolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- DMEKUKDWAIXWSL-UHFFFAOYSA-N n,n-dimethyl-7-nitro-9h-fluoren-2-amine Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(N(C)C)C=C3CC2=C1 DMEKUKDWAIXWSL-UHFFFAOYSA-N 0.000 claims 1
- 238000001783 near-resonance Rayleigh scattering spectroscopy Methods 0.000 claims 1
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100030482 Hypoxia-inducible factor 3-alpha Human genes 0.000 description 1
- 101710083143 Hypoxia-inducible factor 3-alpha Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000232219 Platanista Species 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 108010014806 prothrombinase complex Proteins 0.000 description 1
- 150000003235 pyrrolidines Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11362898P | 1998-12-23 | 1998-12-23 | |
| US12763399P | 1999-04-02 | 1999-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103795B true ZA200103795B (en) | 2002-08-12 |
Family
ID=26811284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103795A ZA200103795B (en) | 1998-12-23 | 2001-05-10 | Nitrogen containing heterobicycles as a factor Xa inhibitors. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6413980B1 (da) |
| EP (1) | EP1140941B1 (da) |
| JP (1) | JP2002533465A (da) |
| KR (1) | KR100628407B1 (da) |
| CN (1) | CN100340559C (da) |
| AR (1) | AR024242A1 (da) |
| AT (1) | ATE280171T1 (da) |
| AU (1) | AU759711B2 (da) |
| BR (1) | BR9917080A (da) |
| CA (1) | CA2349330C (da) |
| DE (1) | DE69921358T2 (da) |
| DK (1) | DK1140941T3 (da) |
| EA (1) | EA004515B1 (da) |
| ES (1) | ES2232202T3 (da) |
| HK (1) | HK1052508B (da) |
| HR (1) | HRP990396A2 (da) |
| IL (2) | IL142959A0 (da) |
| MX (1) | MXPA01006502A (da) |
| MY (1) | MY138239A (da) |
| NO (1) | NO319816B1 (da) |
| NZ (1) | NZ511674A (da) |
| PT (1) | PT1140941E (da) |
| SI (1) | SI1140941T1 (da) |
| TW (1) | TWI225862B (da) |
| WO (1) | WO2000039131A1 (da) |
| ZA (1) | ZA200103795B (da) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501918A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Ｘａ因子阻害剤としての１−（ヘテロアリール−フェニル）−縮合ピラゾール誘導体 |
| US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| EP1854798A3 (en) | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| US6960595B2 (en) * | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
| CA2444571A1 (en) * | 2001-04-18 | 2002-10-31 | Bristol-Myers Squibb Company | 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridin-7-ones as factor xa inhi bitors |
| WO2002085353A1 (en) * | 2001-04-18 | 2002-10-31 | Bristol-Myers Squibb Company | 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor xa inhibitors |
| CA2447488A1 (en) * | 2001-05-22 | 2002-11-28 | Irina Jacobson | Bicyclic inhibitors of factor xa |
| UA78232C2 (uk) | 2001-09-21 | 2007-03-15 | Брістол-Майерс Сквібб Компані | Лактамвмісні сполуки та їх похідні як інгібітори фактора ха |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| AU2002350217A1 (en) * | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| TW200738672A (en) * | 2001-12-10 | 2007-10-16 | Bristol Myers Squibb Co | Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
| AU2002364082A1 (en) * | 2001-12-19 | 2003-07-09 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function |
| ES2373875T3 (es) * | 2002-03-05 | 2012-02-09 | Transtech Pharma, Inc. | Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage. |
| EP1505966A4 (en) * | 2002-05-10 | 2006-08-30 | Bristol Myers Squibb Co | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER |
| AU2003302238A1 (en) | 2002-12-03 | 2004-06-23 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| EP1479678A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Pyrazole-derivatives as factor xa inhibitors |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| MXPA05006200A (es) * | 2002-12-23 | 2005-08-19 | Aventis Pharma Gmbh | Derivados de pirazol como inhibidores del factor xa. |
| US7135469B2 (en) * | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
| US7122557B2 (en) * | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| EP1479675A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| AU2004251599A1 (en) * | 2003-05-20 | 2005-01-06 | Transtech Pharma, Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| AU2004276341B2 (en) | 2003-09-23 | 2011-04-14 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
| KR101290861B1 (ko) | 2004-02-24 | 2013-07-29 | 스미또모 가가꾸 가부시끼가이샤 | 살충제 조성물 |
| CA2575188A1 (en) | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
| US20060069085A1 (en) * | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| KR20070107022A (ko) | 2005-01-07 | 2007-11-06 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| CA2669311C (en) * | 2006-11-13 | 2011-09-20 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
| US20100130514A1 (en) | 2007-04-18 | 2010-05-27 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| CA2682519A1 (en) | 2007-04-18 | 2008-11-06 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| CA2772797C (en) | 2009-09-30 | 2018-09-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives |
| SI2538925T1 (sl) | 2010-02-25 | 2016-04-29 | Bristol-Myers Squibb Company | Apiksaban formulacije |
| US8884016B2 (en) | 2011-06-10 | 2014-11-11 | Dipharma Francis S.R.L. | Apixaban preparation process |
| CN104109165A (zh) * | 2013-04-19 | 2014-10-22 | 四川海思科制药有限公司 | 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用 |
| CN103992310B (zh) * | 2013-05-14 | 2016-07-06 | 中国医学科学院医药生物技术研究所 | 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用 |
| CN104395312B (zh) * | 2013-06-21 | 2016-04-27 | 四川海思科制药有限公司 | 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用 |
| JP6423873B2 (ja) | 2013-07-08 | 2018-11-14 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての６員ｃ−ｎ−結合アリールスルフィド誘導体及びアリールスルホキシド誘導体 |
| CN105745212B (zh) * | 2013-12-06 | 2017-09-12 | 四川海思科制药有限公司 | 取代的4,5‑二氢吡唑并[3,4‑c]吡啶‑2‑酮的螺环衍生物及应用 |
| WO2015162551A1 (en) | 2014-04-21 | 2015-10-29 | Mylan Laboratories Ltd | Process for the preparation of apixaban |
| CN105085515B (zh) * | 2014-05-22 | 2019-02-01 | 华北制药股份有限公司 | 作为凝血因子Xa抑制剂的酰肼类化合物 |
| JP2017516845A (ja) * | 2014-05-22 | 2017-06-22 | ノース チャイナ ファーマシューティカル カンパニー リミテッド | 血液凝固因子Ｘａ阻害剤としてのヒドラジド化合物 |
| ES2800948T3 (es) * | 2014-09-02 | 2021-01-05 | Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd | Derivados de pirazolo[3,4-c]piridina |
| WO2016035007A2 (en) | 2014-09-05 | 2016-03-10 | Unichem Laboratories Limited | An improved process for the preparation of apixaban and intermediates thereof |
| CN104277037B (zh) * | 2014-09-19 | 2015-12-09 | 广东东阳光药业有限公司 | 含有螺环的吡唑并哌啶酮类化合物及其组合物及用途 |
| CN104311575B (zh) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 含有稠环的吡唑并哌啶酮类化合物及其组合物及用途 |
| CN104311555B (zh) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 吡唑并哌啶酮类化合物及其组合物及用途 |
| CN104311556B (zh) * | 2014-09-19 | 2016-06-01 | 广东东阳光药业有限公司 | 含有环氧烷基取代基的吡唑并哌啶酮类化合物及其组合物及用途 |
| CN104311574B (zh) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 含有噻唑的吡唑并哌啶酮类化合物及其组合物及用途 |
| CN104311557B (zh) * | 2014-09-19 | 2016-01-06 | 广东东阳光药业有限公司 | 含有二酮取代基的吡唑并哌啶酮类化合物及其组合物及用途 |
| CN104277039B (zh) * | 2014-09-19 | 2016-06-01 | 广东东阳光药业有限公司 | 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途 |
| CN104530029B (zh) * | 2014-12-09 | 2017-04-12 | 广东东阳光药业有限公司 | 作为Xa因子抑制剂的杂环化合物及其使用方法和用途 |
| CN104513239B (zh) * | 2014-12-10 | 2017-08-22 | 沈阳药科大学 | 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用 |
| US10077263B2 (en) | 2016-04-29 | 2018-09-18 | Optimus Drugs Private Limited | Process for the preparation of Apixaban |
| EP3582777A4 (en) | 2017-02-17 | 2020-12-23 | Unichem Laboratories Ltd | PHARMACEUTICAL COMPOSITION OF APIXABAN |
| CN107235986B (zh) * | 2017-05-27 | 2019-04-12 | 华南师范大学 | 一种合成氮氧杂桥联唑啉化合物的方法 |
| GB201807014D0 (en) | 2018-04-30 | 2018-06-13 | Univ Leeds Innovations Ltd | Factor xlla inhibitors |
| AU2019339777B2 (en) | 2018-09-12 | 2022-09-01 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| KR102128509B1 (ko) * | 2018-12-19 | 2020-07-01 | 한국과학기술연구원 | 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도 |
| CA3155287A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Antiviral pyrazolopyridinone compounds |
| GB202107722D0 (en) | 2021-05-28 | 2021-07-14 | Lunac Therapeutics Ltd | Factor XIIA Inhibitors |
| CA3235765A1 (en) | 2021-11-12 | 2023-05-19 | Jianping Wu | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| CN113956248B (zh) * | 2021-11-12 | 2023-07-04 | 贵州中医药大学 | 一种具有抗炎作用的化合物衍生物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3365459A (en) * | 1964-09-08 | 1968-01-23 | Ciba Geigy Corp | Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives |
| US3340269A (en) * | 1964-09-08 | 1967-09-05 | Ciba Geigy Corp | 1-substituted 4-acyl-2, 3-dioxo-piperidine |
| US3423414A (en) * | 1966-01-13 | 1969-01-21 | Ciba Geigy Corp | Pyrazolopyridines |
| US3939161A (en) * | 1973-10-29 | 1976-02-17 | Abbott Laboratories | 1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones |
| JPS5721388A (en) * | 1980-07-11 | 1982-02-04 | Nippon Nohyaku Co Ltd | Condensed pyrazole derivative |
| JPS63145282A (ja) * | 1986-12-08 | 1988-06-17 | Taiyo Yakuhin Kogyo Kk | ピリダジン誘導体 |
| GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| EP0557526B8 (en) * | 1991-08-07 | 2003-08-13 | Daiichi Suntory Pharma Co., Ltd. | Pyrroloazepine compound |
| WO1994020460A1 (en) | 1993-03-11 | 1994-09-15 | Smithkline Beecham Corporation | Chemical compounds |
| HUT74170A (en) * | 1993-07-06 | 1996-11-28 | Pfizer | Bicyclic tetrahydro pyrazolopyridines |
| PL319758A1 (en) * | 1994-10-20 | 1997-08-18 | Pfizer | Bicyclic tetrahydropyrasole pyridines and their application as medicines |
| US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| AU1345697A (en) * | 1995-12-22 | 1997-07-17 | Du Pont Merck Pharmaceutical Company, The | Novel integrin receptor antagonists |
| EP0807633B1 (en) * | 1996-05-15 | 2002-11-06 | Pfizer Inc. | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones |
| FR2750862B1 (fr) * | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| AU746706B2 (en) * | 1997-07-03 | 2002-05-02 | Du Pont Pharmaceuticals Company | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| DE69920888T2 (de) * | 1998-03-27 | 2006-02-02 | Bristol-Myers Squibb Pharma Co. | Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren |
| DE19845153A1 (de) | 1998-10-01 | 2000-04-06 | Merck Patent Gmbh | Imidazo[4,5]-pyridin-4-on-derivate |
| DE19900471A1 (de) | 1999-01-08 | 2000-07-13 | Merck Patent Gmbh | Imidazo[4,5c]-pyridin-4-on-derivate |
| HUP0203954A2 (hu) | 1999-09-17 | 2003-03-28 | Millennium Pharmaceuticals, Inc. | Xa faktor inhibitorok |
-
1999
- 1999-12-17 BR BR9917080-9A patent/BR9917080A/pt not_active Application Discontinuation
- 1999-12-17 WO PCT/US1999/030316 patent/WO2000039131A1/en active IP Right Grant
- 1999-12-17 AU AU23717/00A patent/AU759711B2/en active Active
- 1999-12-17 DK DK99967444T patent/DK1140941T3/da active
- 1999-12-17 ES ES99967444T patent/ES2232202T3/es not_active Expired - Lifetime
- 1999-12-17 PT PT99967444T patent/PT1140941E/pt unknown
- 1999-12-17 IL IL14295999A patent/IL142959A0/xx unknown
- 1999-12-17 NZ NZ511674A patent/NZ511674A/en not_active IP Right Cessation
- 1999-12-17 KR KR1020017007991A patent/KR100628407B1/ko not_active IP Right Cessation
- 1999-12-17 JP JP2000591042A patent/JP2002533465A/ja active Pending
- 1999-12-17 CN CNB998147710A patent/CN100340559C/zh not_active Expired - Fee Related
- 1999-12-17 EA EA200100688A patent/EA004515B1/ru not_active IP Right Cessation
- 1999-12-17 MX MXPA01006502A patent/MXPA01006502A/es active IP Right Grant
- 1999-12-17 SI SI9930721T patent/SI1140941T1/xx unknown
- 1999-12-17 CA CA002349330A patent/CA2349330C/en not_active Expired - Lifetime
- 1999-12-17 AT AT99967444T patent/ATE280171T1/de active
- 1999-12-17 EP EP99967444A patent/EP1140941B1/en not_active Expired - Lifetime
- 1999-12-17 DE DE69921358T patent/DE69921358T2/de not_active Expired - Lifetime
- 1999-12-21 HR HR990396A patent/HRP990396A2/hr not_active Application Discontinuation
- 1999-12-22 US US09/470,326 patent/US6413980B1/en not_active Expired - Lifetime
- 1999-12-22 MY MYPI99005666A patent/MY138239A/en unknown
- 1999-12-23 AR ARP990106759A patent/AR024242A1/es active IP Right Grant
-
2000
- 2000-01-15 TW TW088122748A patent/TWI225862B/zh not_active IP Right Cessation
-
2001
- 2001-05-03 IL IL142959A patent/IL142959A/en not_active IP Right Cessation
- 2001-05-10 ZA ZA200103795A patent/ZA200103795B/en unknown
- 2001-06-20 NO NO20013072A patent/NO319816B1/no not_active IP Right Cessation
- 2001-07-03 US US09/898,279 patent/US6673810B2/en not_active Expired - Lifetime
-
2003
- 2003-07-04 HK HK03104763.4A patent/HK1052508B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200103795B (en) | Nitrogen containing heterobicycles as a factor Xa inhibitors. | |
| EP3728188B1 (en) | Aryl and heteroaryl substituted indole compounds | |
| EP3313844B1 (en) | Heteroaryl substituted aminopyridine compounds | |
| AU2010271270B2 (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | |
| ES2745525T3 (es) | Compuestos de aminopiridina sustituida con heteroarilo | |
| ES2834027T3 (es) | Compuestos de N-pirrolidinil, N'-pirazolil-urea como inhibidores de TrkA quinasa | |
| KR20200101402A (ko) | Tlr 억제제로서 유용한 치환된 인돌 화합물 | |
| JP2018104463A (ja) | メタロ−β−ラクタマーゼ阻害剤としての３−テトラゾリル−ベンゼン−１，２−ジスルホンアミド誘導体 | |
| WO2017007689A1 (en) | Cot modulators and methods of use thereof | |
| TW201514145A (zh) | 作為ｂｔｋ抑制劑的初級甲醯胺 | |
| JP2022516469A (ja) | ユビキチン特異的プロテアーゼ１を阻害するための組成物 | |
| CA2953798A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| AU2015291478B2 (en) | Novel substituted pyrimidine compounds | |
| TW201838981A (zh) | 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法 | |
| EP4038059B1 (en) | Substituted carbazole compounds | |
| CA2979024C (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| KR20140037821A (ko) | 히스톤 데아세틸라제 억제제 및 그의 조성물 및 사용 방법 | |
| EP3209664A1 (en) | Bicyclic heteroaryl amine compounds as pi3k inhibitors | |
| KR20220118525A (ko) | 벤즈이미다졸 유도체 | |
| EP3229801B1 (en) | Factor ixa inhibitors | |
| EP3258929B1 (en) | Factor ixa inhibitors | |
| JP2022501391A (ja) | 細菌感染症の治療及び予防のための、置換ピリドインドール | |
| EP3870589A1 (en) | Substituted indole dimer compounds | |
| EP4100408B1 (en) | Tricyclic heteroaryl compounds useful as irak4 inhibitors | |
| CA3185597A1 (en) | Plasma kallikrein inhibitors |